MCID: CHG001
MIFTS: 72

Chagas Disease

Categories: Infectious diseases, Rare diseases

Aliases & Classifications for Chagas Disease

MalaCards integrated aliases for Chagas Disease:

Name: Chagas Disease 12 76 53 59 55 43 3 44 15 73
American Trypanosomiasis 12 76 53 59 3
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 53
New World Trypanosomiasis 53
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

59
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 59  
Rare infectious diseases


Summaries for Chagas Disease

NIH Rare Diseases : 53 Chagas disease is caused by the parasite, Trypanosoma cruzi. The triatomine bug, which can carry the parasite, most often bites a person's face and therefore is more commonly known as the "kissing bug". When a triatomine bug infected with Trypanosoma cruzi bites, it can leave behind infected waste which can be spread into the person's eyes, nose, or a wound. Chagas disease can also spread through contaminated food, a blood transfusion, a donated organ, or from mother to baby during pregnancy. Symptoms may include fever, flu-like symptoms, a rash, or swollen eyelid. Early symptoms usually go away without treatment, but can last a few weeks or months. However, if not treated in the early phase, the parasite can become active again years later. In fact, 20-30% of infected people will later develop serious problems affecting their heart, intestines, or espophagus. This risk is greater for those with a weakened immune system. Chagas disease is common in Latin America, but not in the United States. The two drugs used to treat Chagas disease are nifurtimox and benznidazole. On August 30, 2017, the FDA approved benznidazole to treat Chagas disease in children between the ages of 2 to 12 years old. Nifurtimox may also used to treat Chagas disease. Although not FDA approved, nifurtimox can be obtained for the treatment of Chagas disease in the United States through special CDC studies. Similarly, benznidazole is also available through special CDC studies for those with Chagas disease whose treatment is deemed necessary by their doctor but whose age falls outside FDA approval.

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to trypanosomiasis and sleeping sickness, and has symptoms including fever and pruritus. An important gene associated with Chagas Disease is IL10 (Interleukin 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Enalapril and Enalaprilat have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and eye, and related phenotypes are encephalitis and splenomegaly

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

MedlinePlus : 43 Chagas disease is caused by a parasite. It is common in Latin America but not in the United States. Infected blood-sucking bugs, sometimes called kissing bugs, spread it. When the bug bites you, usually on your face, it leaves behind infected waste. You can get the infection if you rub it in your eyes or nose, the bite wound or a cut. The disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. If you notice symptoms, they might include Fever Flu-like symptoms A rash A swollen eyelid These early symptoms usually go away. However, if you don't treat the infection, it stays in your body. Later, it can cause serious intestinal and heart problems. A physical exam and blood tests can diagnose it. You may also need tests to see whether the disease has affected your intestines and heart. Medicines can kill the parasite, especially early on. You can also treat related problems. For example, a pacemaker helps with certain heart complications. There are no vaccines or medicines to prevent Chagas disease. If you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. It is important to use insecticides to prevent bites, and practice food safety. Centers for Disease Control and Prevention

CDC : 3 Chagas disease is named after the Brazilian physician Carlos Chagas, who discovered the disease in 1909. It is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis.

Wikipedia : 76 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 393)
# Related Disease Score Top Affiliating Genes
1 trypanosomiasis 32.0 CALR CCL2 CCL3 IFNG IL10 IL1B
2 sleeping sickness 30.9 IL10 IL6 NOS2
3 idiopathic achalasia 30.8 IL10 NOS2 TNF
4 mucocutaneous leishmaniasis 30.5 CCR5 IL10 TNF
5 cysticercosis 30.3 IL1B IL6 TLR4
6 esophagitis 30.3 IL1B IL6 TGFB1
7 cutaneous leishmaniasis 30.2 IFNG IL10 TLR2 TLR4 TNF
8 myocarditis 30.2 IL6 NOS2 NPPB TNF
9 visceral leishmaniasis 30.1 IFNG IL10 IL2 NOS2 TLR2 TLR4
10 salmonellosis 30.1 IFNG IL1B TLR4
11 membranous nephropathy 30.1 ACE TGFB1 TNF
12 leishmaniasis 30.0 CCL2 CCR5 IFNG IL10 IL1B IL2
13 temporal arteritis 29.8 CCL2 IFNG IL6 TNF
14 filariasis 29.8 IFNG IL10 IL2 IL6 TLR2 TLR4
15 schistosomiasis 29.8 CCL3 IFNG IL10 IL2 TNF
16 acquired immunodeficiency syndrome 29.8 CCL3 CCR5 IFNG IL10 IL1B IL2
17 systolic heart failure 29.7 ACE ADRB1 IL6 NPPB
18 sleep apnea 29.6 ACE IL1B IL6 NPPB TNF
19 autoimmune disease 29.6 CCL2 IFNG IL10 IL1B IL2 IL6
20 malaria 29.6 CCL2 CCL3 IFNG IL10 IL1B IL2
21 psoriasis 29.5 CCL2 IFNG IL10 IL1B IL2 IL6
22 human immunodeficiency virus infectious disease 29.4 CCL3 CCR5 IFNG IL10 IL2 IL6
23 pneumonia 29.4 CCL2 CCL3 IL10 IL1B IL6 TLR2
24 toxoplasmosis 29.4 CCR5 IFNG IL10 IL1B IL6 TLR2
25 arteries, anomalies of 29.3 ACE CCL2 IL1B IL6 NPPB TNF
26 dilated cardiomyopathy 29.2 ACE ADRB1 CALR IL10 IL1B IL6
27 heart disease 29.0 ACE ADRB1 IL10 IL1B IL6 NPPB
28 systemic lupus erythematosus 28.6 ACE CALR CCL2 CCR5 IFNG IL10
29 myocardial infarction 28.6 ACE ADRB1 CCL2 CCR5 IL10 IL1B
30 cephalosporin allergy 10.4 IFNG IL10
31 hyperlucent lung 10.4 IFNG IL10
32 microscopic polyangiitis 10.4 IL10 TNF
33 multifocal choroiditis 10.4 IL10 TNF
34 punctate inner choroidopathy 10.4 IL10 TNF
35 tropical endomyocardial fibrosis 10.4 IL10 TNF
36 inflammatory bowel disease 25, autosomal recessive 10.4 IL10 TGFB1
37 autoimmune myocarditis 10.4 IFNG TNF
38 megacolon 10.4
39 oral tuberculosis 10.4 IL2 TNF
40 juvenile myasthenia gravis 10.4 IL10 TGFB1
41 angioimmunoblastic lymphadenopathy with dysproteinemia 10.4 IL6 TNF
42 exudative glomerulonephritis 10.4 IL1B TNF
43 autoimmune atherosclerosis 10.4 ACE IL10
44 skin sarcoidosis 10.4 ACE TNF
45 uveoparotid fever 10.4 ACE TNF
46 purulent labyrinthitis 10.4 CCL2 IL1B
47 leukomalacia 10.4 IL6 TNF
48 scorpion envenomation 10.4 IL6 TNF
49 subacute cutaneous lupus erythematosus 10.3 ACE TNF
50 achalasia 10.3

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

59 32 (show all 27)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 encephalitis 59 32 very rare (1%) Very rare (<4-1%) HP:0002383
2 splenomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0001744
3 hepatomegaly 59 32 frequent (33%) Frequent (79-30%) HP:0002240
4 fever 59 32 frequent (33%) Frequent (79-30%) HP:0001945
5 dyspnea 59 32 frequent (33%) Frequent (79-30%) HP:0002094
6 arrhythmia 59 32 frequent (33%) Frequent (79-30%) HP:0011675
7 thromboembolism 59 32 frequent (33%) Frequent (79-30%) HP:0001907
8 pallor 59 32 frequent (33%) Frequent (79-30%) HP:0000980
9 abdominal pain 59 32 frequent (33%) Frequent (79-30%) HP:0002027
10 peripheral neuropathy 59 32 very rare (1%) Very rare (<4-1%) HP:0009830
11 congestive heart failure 59 32 occasional (7.5%) Occasional (29-5%) HP:0001635
12 cardiomyopathy 59 32 frequent (33%) Frequent (79-30%) HP:0001638
13 myalgia 59 32 frequent (33%) Frequent (79-30%) HP:0003326
14 aganglionic megacolon 59 32 occasional (7.5%) Occasional (29-5%) HP:0002251
15 achalasia 59 32 occasional (7.5%) Occasional (29-5%) HP:0002571
16 diarrhea 59 32 frequent (33%) Frequent (79-30%) HP:0002014
17 myocarditis 59 32 frequent (33%) Frequent (79-30%) HP:0012819
18 skin rash 59 32 frequent (33%) Frequent (79-30%) HP:0000988
19 cough 59 32 frequent (33%) Frequent (79-30%) HP:0012735
20 periorbital edema 59 32 frequent (33%) Frequent (79-30%) HP:0100539
21 headache 59 32 frequent (33%) Frequent (79-30%) HP:0002315
22 lymphadenopathy 59 32 frequent (33%) Frequent (79-30%) HP:0002716
23 abnormal large intestine physiology 59 32 occasional (7.5%) Occasional (29-5%) HP:0012700
24 localized skin lesion 59 32 frequent (33%) Frequent (79-30%) HP:0011355
25 autoimmune antibody positivity 59 32 frequent (33%) Frequent (79-30%) HP:0030057
26 edema 59 Frequent (79-30%)
27 abnormality of the nervous system 59 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 ACE IL10 IL1B IL2 NOS2 TGFB1

MGI Mouse Phenotypes related to Chagas Disease:

46 (show all 23)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
2 growth/size/body region MP:0005378 10.43 ACE ADRB1 CALR CYP51A1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.41 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
4 immune system MP:0005387 10.4 ACE CCL2 CCR5 CYP51A1 IFNG IL10
5 behavior/neurological MP:0005386 10.38 ACE CCR5 IFNG IL10 IL2 IL6
6 mortality/aging MP:0010768 10.38 ACE ADRB1 CALR CCR5 CYP51A1 IFNG
7 hematopoietic system MP:0005397 10.36 ACE CCR5 IFNG IL10 IL1B IL2
8 cellular MP:0005384 10.33 CALR CCR5 IFNG IL10 IL2 IL6
9 digestive/alimentary MP:0005381 10.32 CCR5 CYP51A1 IFNG IL10 IL2 IL6
10 endocrine/exocrine gland MP:0005379 10.27 ACE ADRB1 IFNG IL10 IL2 IL6
11 muscle MP:0005369 10.27 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
12 liver/biliary system MP:0005370 10.24 ACE CCR5 IFNG IL10 IL2 IL6
13 adipose tissue MP:0005375 10.21 ACE ADRB1 IL6 NOS2 TGFB1 TLR2
14 integument MP:0010771 10.21 IFNG IL10 IL1B IL6 NOS2 NTRK1
15 neoplasm MP:0002006 10.21 ACE CCR5 IFNG IL10 IL1B IL2
16 nervous system MP:0003631 10.18 CALR CCR5 IFNG IL10 IL1B IL6
17 craniofacial MP:0005382 10.13 CYP51A1 IFNG IL10 IL1B NOS2 TGFB1
18 no phenotypic analysis MP:0003012 9.97 ADRB1 CCR5 CYP51A1 IFNG IL10 IL2
19 reproductive system MP:0005389 9.96 ACE CCR5 IFNG IL10 IL2 IL6
20 renal/urinary system MP:0005367 9.87 ACE IFNG IL6 NOS2 TGFB1 TLR2
21 respiratory system MP:0005388 9.81 IFNG IL10 IL2 IL6 NOS2 TGFB1
22 skeleton MP:0005390 9.7 ADRB1 CYP51A1 IFNG IL10 IL1B IL6
23 vision/eye MP:0005391 9.32 CCR5 IFNG IL10 IL2 IL6 NOS2

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 100)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
2
Enalaprilat Approved Phase 4 76420-72-9 6917719
3
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Zidovudine Approved Phase 4 30516-87-1 35370
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
8
Efavirenz Approved, Investigational Phase 4,Phase 3 154598-52-4 64139
9
Didanosine Approved Phase 4 69655-05-6 50599
10
Ritonavir Approved, Investigational Phase 4,Phase 3 155213-67-5 392622
11
Nevirapine Approved Phase 4 129618-40-2 4463
12
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
13
Coumarin Experimental Phase 4 91-64-5 323
14
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
15 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Not Applicable
17 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
19 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Benzonidazole Phase 4,Phase 3,Phase 2,Not Applicable
21
protease inhibitors Phase 4,Phase 3
22 Adrenergic alpha-1 Receptor Antagonists Phase 4
23 Natriuretic Peptide, Brain Phase 4
24 Neurotransmitter Agents Phase 4,Phase 3
25 Antihypertensive Agents Phase 4,Phase 3
26 Adrenergic Antagonists Phase 4,Phase 3
27 Adrenergic alpha-Antagonists Phase 4
28 HIV Protease Inhibitors Phase 4,Phase 3
29 Adrenergic beta-Antagonists Phase 4,Phase 3
30 Adrenergic Agents Phase 4,Phase 3
31 Angiotensin-Converting Enzyme Inhibitors Phase 4
32 Vasodilator Agents Phase 4,Phase 3,Not Applicable
33 Anticoagulants Phase 4
34 Lamivudine, zidovudine drug combination Phase 4
35 Antiviral Agents Phase 4,Phase 3
36 Cytochrome P-450 CYP3A Inducers Phase 4
37 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
38 Anti-HIV Agents Phase 4,Phase 3
39 Antimetabolites Phase 4
40 Atazanavir Sulfate Phase 4
41 Cytochrome P-450 CYP2C19 Inhibitors Phase 4
42 Reverse Transcriptase Inhibitors Phase 4
43 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
44 Anti-Retroviral Agents Phase 4,Phase 3
45 Cytochrome P-450 CYP2C9 Inhibitors Phase 4,Phase 3,Not Applicable
46 Nucleic Acid Synthesis Inhibitors Phase 4
47 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Not Applicable
48 Analgesics, Non-Narcotic Phase 4,Phase 3
49 Peripheral Nervous System Agents Phase 4,Phase 3
50 Analgesics Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4 Benznidazole
2 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Completed NCT01678599 Phase 4 Benznidazole
3 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Completed NCT01549236 Phase 4 Benznidazole 12,5mg or 100mg
4 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
5 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4 RASi plus carvedilol
6 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
7 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed NCT00084136 Phase 4 Atazanavir;Didanosine (enteric-coated);Efavirenz;Emtricitabine;Emtricitabine/Tenofovir disoproxil fumarate;Lamivudine/Zidovudine
8 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
9 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4 Aspirin
10 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
11 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3 Benznidazole;Placebo
12 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3 Benznidazole;Placebo
13 Physical Exercise Program in Chronic Chagas Heart Disease Completed NCT02517632 Phase 3
14 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
15 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3 Bisoprolol
16 Interleukin-2 Plus Antiretroviral Therapy for HIV-Infected Patients With Low CD4+ Counts (SILCAAT Study) Completed NCT00013611 Phase 3 Proleukin
17 An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy Completed NCT00004978 Phase 3 Recombinant interleukin-2 (rIL-2)
18 Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients Completed NCT01348308 Phase 3 Maraviroc (Celsentri);Placebo
19 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3 Selenium;Placebo (for Selenium)
20 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3 Nifurtimox;Benznidazole;Placebo
21 A Trial Testing Amiodarone in Chagas Cardiomiopathy Recruiting NCT03193749 Phase 3 Amiodarone Hydrochloride;Placebo Oral Tablet
22 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Active, not recruiting NCT02625974 Phase 3 Nifurtimox (BAYA2502);Nifurtimox (BAYA2502) followed by Placebo
23 Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age Not yet recruiting NCT03672487 Phase 3 Benznidazole;Placebo Oral Tablet
24 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3 melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d;melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d;nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d
25 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3 Filgrastime (G-CSF);Standart therapy
26 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2 E1224;Benznidazole;Placebo
27 Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease Unknown status NCT02498782 Phase 2 Fexinidazole;Placebo
28 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2 Posaconazole;Placebo for posaconazole;Benznidazole
29 Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole Completed NCT01162967 Phase 2 Benznidazole;Posaconazole
30 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy Completed NCT00629018 Phase 2 Bone Marrow Stimulation
31 Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease Recruiting NCT03587766 Phase 2 Fexinidazole;Placebo Oral Tablet
32 Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease. Recruiting NCT03191162 Phase 2 Benznidazole
33 BENDITA BEnznidazole New Doses Improved Treatment and Associations Active, not recruiting NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
34 Colchicine for Patients With Chagas´ Disease( B1 Stage) Active, not recruiting NCT03704181 Phase 2 Colchicine 0.5 MG twice day for one year;Placebo Oral Tablet
35 Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy Enrolling by invitation NCT02154269 Phase 2 Treatment with G-CSF (Granulocyte colony stimulating factor);Placebo saline
36 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT02606864 Phase 1 Nifurtimox (BAYa2502)
37 Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients Completed NCT01927224 Phase 1 Nifurtimox (BAYa2502) (4 x 30 mg tablet);Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water);Nifurtimox (BAYa2502) (120 mg tablet)
38 Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg Completed NCT03350295 Phase 1 Nifurtimox (Lampit, BAYA2502)
39 Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation Recruiting NCT03708133 Phase 1 Nifurtimox (Lampit, BAYA2502)_Test;Nifurtimox (Lampit, BAYA2502)_Reference
40 Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study Not yet recruiting NCT03334838 Phase 1 Nifurtimox (Lampit, BAYA2502)
41 Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram Unknown status NCT00453700 Not Applicable
42 Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease Unknown status NCT02099903 Not Applicable
43 Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction Unknown status NCT02295215 Not Applicable
44 Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease Unknown status NCT01566617 Not Applicable
45 Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias Unknown status NCT01847378
46 Measurement of Antibodies in Adults With a History of Kawasaki Disease Unknown status NCT02853266
47 Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease Completed NCT02327052
48 MicroRNAs as Biomarkers in Patients With Chagas Disease Completed NCT01842880
49 Galectin-3 as a Biomarker in Patients With Chagas Disease Completed NCT01842854
50 Syndecan-4 as a Biomarker in Patients With Chagas Disease Completed NCT01842867

Search NIH Clinical Center for Chagas Disease

Cochrane evidence based reviews: chagas disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

41
Heart, Testes, Eye, Colon, T Cells, Lymph Node, Bone

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 1749)
# Title Authors Year
1
Anticoagulation in patients with cardiac manifestations of Chagas disease and cardioembolic ischemic stroke. ( 29364390 )
2018
2
Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment. ( 29412353 )
2018
3
Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole. ( 29452113 )
2018
4
Atrial fibrillation in acute Chagas disease acquired via oral transmission: a case report. ( 29972578 )
2018
5
Molecular characterization of Rhodnius robustus specimens, potential vectors for Chagas disease in French Guiana, South America. ( 29378264 )
2018
6
Corrigendum: Lipid Bodies as Sites of Prostaglandin E2 Synthesis During Chagas Disease: Impact in the Parasite Escape Mechanism. ( 29888755 )
2018
7
Chagas disease cardiomyopathy treatment remains a challenge - Authors' reply. ( 29893217 )
2018
8
Chagas Disease Recommendations for Solid-Organ Transplant Recipients and Donors. ( 29381572 )
2018
9
Evaluation of parasite and host genetics in two generations of a family with Chagas disease. ( 29922960 )
2018
10
Chagas Disease Surveillance Activities - Seven States, 2017. ( 29975678 )
2018
11
Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial. ( 29352704 )
2018
12
The long road towards a safe and effective treatment of chronic Chagas disease. ( 29352705 )
2018
13
Treatment with low doses of aspirin during chronic phase of experimental Chagas' disease increases oesophageal nitrergic neuronal subpopulation in mice. ( 29349896 )
2018
14
Prevalence of Chagas Disease among Solid Organ-Transplanted Patients in a Nonendemic Country. ( 29405102 )
2018
15
High prevalence of S. Stercoralis infection among patients with Chagas disease: A retrospective case-control study. ( 29385128 )
2018
16
Quantitative and histological assessment of maternal-fetal transmission of Trypanosoma cruzi in guinea pigs: An experimental model of congenital Chagas disease. ( 29364882 )
2018
17
Role of Hormonal Circuitry Upon T Cell Development in Chagas Disease: Possible Implications on T Cell Dysfunctions. ( 29963015 )
2018
18
Electrocardiographic abnormalities in Chagas disease in the general population: A systematic review and meta-analysis. ( 29897909 )
2018
19
Extracellular Vesicles in Chagas Disease: A New Passenger for an Old Disease. ( 29910793 )
2018
20
Chronic Chagas disease: therapeutic protocols and efficacy endpoints. ( 29976524 )
2018
21
Chagas disease and systemic autoimmune diseases among Bolivian patients in Switzerland. ( 29412344 )
2018
22
Chagas disease cardiomyopathy treatment remains a challenge. ( 29893218 )
2018
23
Comprehensive analysis of three TYK2 gene variants in the susceptibility to Chagas disease infection and cardiomyopathy. ( 29304122 )
2018
24
The Use of Microvolt T-Wave Alternans in Chagas Disease. ( 29898040 )
2018
25
Pathogenesis of Chronic Chagas Disease: Macrophages, Mitochondria, and Oxidative Stress. ( 29868332 )
2018
26
Ageing with Chagas disease: an overview of an urban Brazilian cohort in Rio de Janeiro. ( 29914550 )
2018
27
Toxicity of nifurtimox as second-line treatment after benznidazole intolerance in patients with chronic Chagas disease: When available options fail. ( 29906591 )
2018
28
Non-randomized controlled trial of the long-term efficacy of an Ecohealth intervention against Chagas disease in Yucatan, Mexico. ( 29965992 )
2018
29
Complementary Paths to Chagas Disease Elimination: The Impact of Combining Vector Control With Etiological Treatment. ( 29860294 )
2018
30
&amp;quot;It's Like a Phantom Disease&amp;quot;: Patient Perspectives on Access to Treatment for Chagas Disease in the United States. ( 29380723 )
2018
31
Nucleotide and nucleoside involvement in immunomodulation in experimental Chagas disease. ( 29404886 )
2018
32
Microbiomes of North American Triatominae: The Grounds for Chagas Disease Epidemiology. ( 29951039 )
2018
33
Pupillometry in Chagas disease. ( 29924199 )
2018
34
cDNA Isolation and Expression of Nicotinamide Adenine Dinucleotide Phosphate-Dependent Cytochrome P450 Reductase Gene in the Chagas Disease Vector<i>Triatoma infestans</i>. ( 29363459 )
2018
35
Systematic neonatal screening for congenital Chagas disease in Northeast Brazil: prevalence of Trypanosoma cruzi infection in the Southern region of Sergipe. ( 29972561 )
2018
36
Socioeconomic benefit to individuals of achieving 2020 targets for four neglected tropical diseases controlled/eliminated by innovative and intensified disease management: Human African trypanosomiasis, leprosy, visceral leishmaniasis, Chagas disease. ( 29534061 )
2018
37
Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against Chagas disease. ( 29357372 )
2018
38
What to expect and when: benznidazole toxicity in chronic Chagas' disease treatment. ( 29351667 )
2018
39
Daily activity patterns of movement and refuge use in Triatoma gerstaeckeri and Rhodnius prolixus (Hemiptera: Reduviidae), vectors of the Chagas disease parasite. ( 29908170 )
2018
40
Complete Mitochondrial Genome of the Chagas Disease Vector, Triatoma rubrofasciata. ( 30419739 )
2018
41
Evolution of incidence and geographical distribution of Chagas disease in Mexico during a decade (2007-2016). ( 30421698 )
2018
42
Continuing evidence of Chagas disease along the Texas-Mexico border. ( 30427833 )
2018
43
Virulence of Trypanosoma cruzi from vector and reservoir in in natura açaí pulp resulting in food-borne acute Chagas disease at Pará State, Brazil. ( 30439347 )
2018
44
Thiazole, thio and semicarbazone derivatives against tropical infective diseases: Chagas disease, human African trypanosomiasis (HAT), leishmaniasis, and malaria. ( 30453246 )
2018
45
Renal dysfunction in Leishmaniasis and Chagas disease coinfection: a case report. ( 30462796 )
2018
46
Discovery of Non-Peptidic Compounds against Chagas Disease Applying Pharmacophore Guided Molecular Modelling Approaches. ( 30469538 )
2018
47
Simultaneous use of two rapid diagnostic tests for the diagnosis of Chagas disease. ( 30482107 )
2018
48
Chagas disease reactivation: cutaneous manifestations in a transplanted patient. ( 30484538 )
2018
49
Chagas disease: An underrecognized diagnosis. ( 30489388 )
2018
50
Integrating evidence, models and maps to enhance Chagas disease vector surveillance. ( 30496172 )
2018

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.16 CALR CCL2 CCL3 CCR5 IFNG IL10
2
Show member pathways
13.98 ADRB1 CCL2 CCL3 CCR5 IL10 IL1B
3
Show member pathways
13.83 CCL2 CCL3 CCR5 IFNG IL10 IL1B
4
Show member pathways
13.66 CCL2 CCL3 IFNG IL10 IL1B IL2
5
Show member pathways
13.55 CCL2 CCL3 CCR5 IL10 IL1B IL2
6
Show member pathways
13.52 CCL2 CCL3 CCR5 IFNG IL10 IL1B
7
Show member pathways
13.45 CCL2 CCL3 CCR5 IL10 IL1B IL2
8
Show member pathways
13.23 CALR CCL2 CCL3 CCR5 IL1B IL6
9
Show member pathways
13.13 ACE CCL2 IL2 IL6 NTRK1 TGFB1
10
Show member pathways
13.08 IL2 IL6 NTRK1 TLR2 TLR4 TNF
11
Show member pathways
13.04 CALR IFNG IL10 IL1B IL2 IL6
12
Show member pathways
13.02 ACE CALR CCL2 CCL3 IFNG IL10
13
Show member pathways
12.98 CCL2 IFNG IL1B IL2 IL6 TLR2
14 12.94 IFNG IL2 IL6 NOS2 NTRK1 TGFB1
15
Show member pathways
12.87 IL1B IL2 IL6 TGFB1 TLR2 TLR4
16
Show member pathways
12.83 IFNG IL1B IL6 TLR4 TNF
17
Show member pathways
12.78 CCL2 IFNG IL10 IL1B IL2 IL6
18 12.75 CCL2 IFNG IL10 IL1B IL2 TLR2
19
Show member pathways
12.73 IFNG IL10 IL1B IL2 IL6 TGFB1
20
Show member pathways
12.59 CCR5 IFNG IL10 IL1B IL2 IL6
21 12.54 CALR IL2 IL6 TGFB1 TNF
22
Show member pathways
12.51 CCR5 IFNG IL10 IL2 IL6
23
Show member pathways
12.51 CCL2 IFNG IL1B IL2 IL6 TNF
24
Show member pathways
12.51 CCL2 IFNG IL1B IL6 TLR2 TNF
25
Show member pathways
12.49 IFNG IL1B IL6 NOS2 TLR4 TNF
26
Show member pathways
12.46 IFNG IL10 IL1B IL2 IL6 NTRK1
27
Show member pathways
12.44 CCR5 IFNG IL10 IL1B NOS2 TGFB1
28 12.38 IFNG IL10 IL1B IL6 NOS2 TGFB1
29 12.37 CALR IL6 TLR2 TNF
30 12.37 TGFB1 TLR2 TLR4 TNF
31
Show member pathways
12.37 IL1B IL6 NOS2 TLR2 TNF
32
Show member pathways
12.37 IFNG IL1B IL6 NOS2 TLR2 TLR4
33
Show member pathways
12.36 IL10 IL1B IL2 IL6 TNF
34
Show member pathways
12.36 ACE ADRB1 IL6 TGFB1 TNF
35 12.36 IFNG IL6 NOS2 TGFB1 TLR2 TLR4
36
Show member pathways
12.34 IL6 TLR2 TLR4 TNF
37
Show member pathways
12.33 CCL2 CCL3 CCR5 IL1B TLR2 TLR4
38
Show member pathways
12.3 IFNG IL1B TLR4 TNF
39 12.27 IL10 IL1B IL6 TNF
40
Show member pathways
12.27 CCL2 CCL3 IFNG IL10 IL1B IL2
41
Show member pathways
12.25 IFNG IL1B IL6 TLR2 TLR4 TNF
42
Show member pathways
12.2 IFNG IL10 IL1B IL2 IL6 TGFB1
43 12.19 CCL2 IFNG IL1B TNF
44
Show member pathways
12.19 CCL3 CCR5 IFNG IL1B IL2 NOS2
45 12.17 IFNG IL10 IL2 IL6 TNF
46 12.15 IFNG IL1B TGFB1 TNF
47 12.15 CCL2 IL10 IL1B IL6 NOS2 TGFB1
48
Show member pathways
12.14 IL1B IL2 TLR2 TLR4
49 12.13 CCL3 IFNG IL1B IL6 TGFB1
50 12.1 CCL2 IL1B IL6 TGFB1 TNF

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ACE CALR CCL2 CCL3 IFNG IL10
2 cell surface GO:0009986 9.7 CALR CCR5 NTRK1 TGFB1 TLR2 TLR4
3 external side of plasma membrane GO:0009897 9.65 ACE CALR CCR5 TLR4 TNF
4 extracellular space GO:0005615 9.4 ACE CALR CCL2 CCL3 IFNG IL10

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 93)
# Name GO ID Score Top Affiliating Genes
1 cellular response to interferon-gamma GO:0071346 9.99 CCL2 CCL3 NOS2 TLR2 TLR4
2 response to organic substance GO:0010033 9.98 CALR IL10 TGFB1 TNF
3 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.98 IL1B IL6 NTRK1 TGFB1 TLR2 TLR4
4 positive regulation of inflammatory response GO:0050729 9.97 CCL3 IL2 TLR2 TLR4 TNF
5 regulation of insulin secretion GO:0050796 9.96 IFNG IL1B NOS2 TNF
6 response to glucocorticoid GO:0051384 9.96 IL10 IL1B IL6 TNF
7 cellular response to organic cyclic compound GO:0071407 9.96 CCL2 CCL3 IL1B TGFB1 TNF
8 inflammatory response GO:0006954 9.96 CCL2 CCL3 CCR5 IL10 IL1B IL6
9 cell chemotaxis GO:0060326 9.95 CCL2 CCL3 CCR5
10 defense response to Gram-negative bacterium GO:0050829 9.95 IL6 NOS2 TLR4
11 neutrophil chemotaxis GO:0030593 9.94 CCL2 CCL3 IL1B
12 positive regulation of JNK cascade GO:0046330 9.94 IL1B TLR4 TNF
13 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.94 IL6 TGFB1 TNF
14 cellular response to mechanical stimulus GO:0071260 9.94 IL1B TGFB1 TLR4
15 humoral immune response GO:0006959 9.94 CCL2 IFNG IL6 TNF
16 chemokine-mediated signaling pathway GO:0070098 9.93 CCL2 CCL3 CCR5
17 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.93 IFNG IL2 IL6
18 positive regulation of T cell proliferation GO:0042102 9.92 IL1B IL2 IL6
19 positive regulation of interferon-gamma production GO:0032729 9.92 IL1B IL2 TLR4 TNF
20 positive regulation of interleukin-6 production GO:0032755 9.92 IL1B IL6 TLR2 TLR4 TNF
21 cellular response to lipopolysaccharide GO:0071222 9.92 CCL2 CCR5 IL10 IL1B IL6 NOS2
22 positive regulation of tumor necrosis factor production GO:0032760 9.91 CCL3 TLR2 TLR4
23 positive regulation of nitric oxide biosynthetic process GO:0045429 9.91 IFNG IL1B TLR4 TNF
24 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.91 CALR IL1B TLR2 TLR4 TNF
25 negative regulation of fat cell differentiation GO:0045599 9.9 IL6 TGFB1 TNF
26 extrinsic apoptotic signaling pathway GO:0097191 9.9 IFNG TGFB1 TNF
27 monocyte chemotaxis GO:0002548 9.9 CCL2 CCL3 IL6
28 immune response GO:0006955 9.9 CCL2 CCL3 CCR5 IFNG IL10 IL1B
29 positive regulation of phagocytosis GO:0050766 9.89 CALR IL1B TNF
30 negative regulation of mitotic cell cycle GO:0045930 9.89 IL10 TGFB1 TNF
31 negative regulation of interleukin-6 production GO:0032715 9.88 IL10 TLR4 TNF
32 positive regulation of interleukin-8 production GO:0032757 9.88 IL1B TLR2 TLR4 TNF
33 negative regulation of neurogenesis GO:0050768 9.86 IL1B IL6 TNF
34 positive regulation of interleukin-12 production GO:0032735 9.86 IFNG TLR2 TLR4
35 positive regulation of protein complex assembly GO:0031334 9.86 IFNG TGFB1 TNF
36 protein import into nucleus, translocation GO:0000060 9.85 IFNG TGFB1 TNF
37 positive regulation of glial cell proliferation GO:0060252 9.85 IL1B IL6 TNF
38 protein kinase B signaling GO:0043491 9.85 CCL2 CCL3 IL1B TGFB1 TNF
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.84 IFNG IL1B TNF
40 regulation of regulatory T cell differentiation GO:0045589 9.84 IFNG IL2 TGFB1
41 positive regulation of chemokine production GO:0032722 9.84 IL6 TLR2 TLR4 TNF
42 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 IL10 IL1B TNF
43 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.82 CCL2 TLR2 TLR4
44 cell activation GO:0001775 9.81 CCL3 TGFB1 TLR2
45 negative regulation of interleukin-17 production GO:0032700 9.8 IFNG TGFB1 TLR4
46 response to cholesterol GO:0070723 9.8 CCL3 CCR5 TGFB1
47 I-kappaB phosphorylation GO:0007252 9.77 TLR2 TLR4
48 positive regulation of immunoglobulin secretion GO:0051024 9.77 IL2 IL6
49 positive regulation of regulatory T cell differentiation GO:0045591 9.77 IL2 TGFB1
50 response to molecule of bacterial origin GO:0002237 9.77 IL10 TLR2

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL10 IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.28 CCL2 CCL3 IFNG IL10 IL1B IL2
3 lipopolysaccharide receptor activity GO:0001875 8.96 TLR2 TLR4
4 protein binding GO:0005515 10.19 ADRB1 CALR CCL2 CCL3 CCR5 IFNG

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....